In brief
Eli Lilly CEO Dave Ricks argues that drug development is slow, risky and expensive because biology is still poorly understood, and that no amount of computing power removes that. Most Lilly scientists never work on a drug that reaches patients. Lilly's answer is speed, plus a focus on problems that cause the most human suffering at scale rather than where the market is today.
The main tension is between innovation and affordability. Ricks says medicines that are clearly valuable earn a premium and later become cheap generics. He also admits the US financing system leaves people exposed to high out-of-pocket drug costs and unequal coverage. He wants incremental, tested policy changes, not sudden swings, and sees obesity drugs funding a push into brain health.
Facts
Stated by the speakers. Each quote matches the transcript, which shows what was said, not that it is true.
Dave Ricks says drug development across the pharmaceutical industry takes 13 or 14 years in total, and most Eli Lilly scientists never work on a successful drug in their careers.
“In total, in the industry, that takes 13 or 14 years. Most of our scientists, the thousands of people who work here, actually never work on something that's successful in their whole career.”
0:03:19 · Dave Ricks · Drug development
Dave Ricks says Eli Lilly has cut its drug development times roughly in half and fails faster than other companies.
“we've cut our times in roughly half. So we're failing a lot faster than others.”
0:04:37 · Dave Ricks · Development speed
Dave Ricks says he spends roughly 25 to 30 percent of his time working with Eli Lilly's scientific team.
“I probably spend, I don't know, 25, 30 % of my time working with the scientific team”
0:03:41 · Dave Ricks · CEO role
Dave Ricks says Alphabet led a major breakthrough on protein folding with AlphaFold.
“there was a big breakthrough on protein folding that Alphabet led in AlphaFold.”
0:05:38 · Dave Ricks · AlphaFold
Dave Ricks predicts machine-aided drug discovery and development will be the standard approach in about ten years.
“machine-aided drug development and drug discovery, I think, in 10 years would be the way.”
0:06:13 · Dave Ricks · AI in drug discovery
Dave Ricks says Americans on average pay about 3 percent of hospital costs out of pocket but about 20 percent of pharmacy costs.
“So if you go to the hospital, we pay 3 % of that cost out-of-pocket in the US on average. If we go to the pharmacy, we pay 20 % out-of-pocket.”
0:10:44 · Dave Ricks · Out-of-pocket costs
Dave Ricks says Eli Lilly invented Prozac, which is now a cheap generic standard of care for depression worldwide.
“we invented Prozac, which is a standard of care to treat depression globally. It's almost free.”
0:11:41 · Dave Ricks · Prozac
Dave Ricks says the first incretin hormone, GLP-1, was made into a drug in 2005.
“The first one we identified and made a drug out of was GLP-1. Actually, we did that in 2005.”
0:14:22 · Dave Ricks · GLP-1 drugs · 2005
Dave Ricks says Novo Nordisk ran the studies that revealed the weight-loss effect of weekly GLP-1 drugs, and Eli Lilly followed with its GLP-1 drug Trulicity.
“Novo Nordisk actually did those studies and we followed, we had a drug called Trulicity, still do.”
0:14:50 · Dave Ricks · GLP-1 drugs
Dave Ricks says tirzepatide is a dual-acting drug that uses two gut hormones, GLP-1 and GIP.
“Tirzepatide is a dual acting. So it uses two hormones.”
0:14:50 · Dave Ricks · Tirzepatide
Dave Ricks says about a billion people worldwide, including 100 million Americans, are overweight or have obesity.
“a billion people on planet earth have obesity overweight that's a lot 100 million americans”
0:15:31 · Dave Ricks · Obesity prevalence
Dave Ricks estimates that about 40 percent of US healthcare spending is tied to obesity.
“Maybe 40 % of US healthcare spending is tied to obesity.”
0:15:31 · Dave Ricks · Obesity costs
Dave Ricks says tirzepatide reduces body weight by about 20 percent on average.
“And so it's really helping reduce weight on average 20 % of body weight.”
0:16:00 · Dave Ricks · Tirzepatide
Dave Ricks says a Lilly study showed tirzepatide reduced new diabetes diagnoses by 94 percent.
“now we're demonstrating it also affects the downstream diseases, like we just showed, it reduced new diabetes diagnosis by 94%.”
0:16:00 · Dave Ricks · Tirzepatide
Dave Ricks says that in Lilly's clinical trials, people on strict diet and exercise regimens lost at most about 5 percent of body weight after a year.
“we put people on strict diets and exercise. and after about a year, they lose about 5 % at most of their body weight.”
0:17:12 · Dave Ricks · Diet and exercise
Dave Ricks says US taxpayers do not currently pay for obesity drugs because the government does not reimburse them, though about half of commercial payers do.
“In the U.S., it's important to note that taxpayers are bearing none of the cost. The U.S. doesn't reimburse these.”
0:16:42 · Dave Ricks · Obesity drug coverage
Dave Ricks says Eli Lilly originated the $35 out-of-pocket cap on insulin, starting it in 2019 in the employer market.
“Actually, Lilly invented that. We started doing that in 2019 for the markets where we could, which is the employer market.”
0:22:00 · Dave Ricks · Insulin cap · 2019
Dave Ricks says Lilly proposed the insulin out-of-pocket cap to the prior US administration as a Medicare experiment, and the current administration later made it law.
“We then took that to the prior administration and said, why don't we try this as an experiment in Medicare?”
0:22:00 · Dave Ricks · Insulin cap
Dave Ricks says he spent time running Eli Lilly's Canadian business and lived in Canada.
“I spent some time running our Canadian business and lived there.”
0:21:00 · Dave Ricks · Career
Dave Ricks says many telehealth visits allowed during the pandemic were later cut, which he regards as a loss of efficiency.
“we allowed for a lot of telehealth visits during the pandemic Those then got cut.”
0:24:26 · Dave Ricks · Telehealth
Dave Ricks cites Eli Lilly's latest Alzheimer's drug as an example of progress against neurodegenerative disease.
“Our latest Alzheimer's drug, Kassanla, is an example of that.”
0:29:41 · Dave Ricks · Alzheimer's
Dave Ricks says Lilly and others might have good non-opioid pain drugs in five to seven years.
“that maybe in five to seven years, we could have good pain drugs that can alleviate the need for opioids.”
0:30:48 · Dave Ricks · Pain drugs
Dave Ricks says Eli Lilly led a wave of mental-health innovation with Prozac and Zyprexa, but there has been little since.
“Mental health, there was a big wave of innovation Lilly led with drugs like Prozac or Zyprexa for bipolar and schizophrenia.”
0:30:48 · Dave Ricks · Mental health
Dave Ricks says the biggest change behind rising obesity over 40 years is processed foods, more than exercise or quantity of food.
“That's a little bit true, but the biggest thing that's changed is processed foods.”
0:26:32 · Dave Ricks · Obesity causes
Dave Ricks says Eli Lilly has now caught up with supply of its obesity drug, but only just.
“we have a situation where we're now caught up with supply, but just”
0:18:01 · Dave Ricks · Drug supply